Company Encyclopedia
View More
name
Dizal Pharmaceutical
688192.SH
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shanghai, China.
1.554 T
688192.SHMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking23/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-92.83%E
    • Profit Margin-142.73%E
    • Gross Margin95.81%A
  • Growth ScoreA
    • Revenue YoY55.98%A
    • Net Profit YoY-3.61%C
    • Total Assets YoY79.93%A
    • Net Assets YoY230.19%A
  • Cash ScoreB
    • Cash Flow Margin-70.06%D
    • OCF YoY55.98%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreC
    • Gearing Ratio51.15%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tianma Microelectronics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Tianma Microelectronics Co., Ltd. reported earnings for the nine months ending September 30, 2025, with sales of CNY 26,662.7 million, up from CNY 24,014.02 million the previous year. The company achieved a net income of CNY 313.12 million, recovering from a net loss of CNY 472.62 million a year ago. Basic and diluted earnings per share from continuing operations were CNY 0.1274, compared to losses of CNY 0.1923 in the prior year.

    marketscreener·
    SZ
    000050
    -0.68%
    marketscreener·
    SZ
    000050
    -0.68%

    Dizal Pharmaceutical released its performance for the first three quarters, with a net loss attributable to the parent company of 580 million yuan

    According to the Zhitong Finance APP, Dizal Pharmaceutical disclosed its third-quarter report for 2025, stating that the company achieved revenue of 586 million yuan in the first three quarters, a year-on-year increase of 73.23%; the net profit attributable to the parent company was a loss of 580 million yuan; the net profit excluding non-recurring gains and losses was a loss of 631 million yuan; and the basic earnings per share were -1.32 yuan

    Zhitong·
    SH
    688192
    +2.72%
    Zhitong·
    SH
    688192
    +2.72%

    Guangfa Securities: The long-term positive trend in the industry has been established; BD is just the starting point for the current round of innovative drug value reassessment

    Guangfa Securities released a research report indicating that under the backdrop of innovation upgrading and internationalization, the domestic pharmaceutical industry is gradually shifting from following innovation to leading innovation, and it is expected to usher in a new round of investment opportunities in the product cycle in the medium to long term. In the first half of 2025, the pharmaceutical industry's operating revenue year-on-year growth rate was -2.3%, but profitability continued to improve. Among the 16 Hong Kong-listed pharmaceutical companies, 9 companies achieved positive growth in operating revenue, and 11 companies reported positive growth in net profit attributable to the parent company after deducting non-recurring gains and losses. Biotech companies saw a year-on-year revenue increase of 24.6%, mainly benefiting from the launch of new products and accelerated internationalization

    Zhitong·
    SH
    688235
    +0.92%
    US
    BGNE
    0.00%
    HK
    06160
    -1.39%
    Zhitong·
    SH
    688235
    +0.92%
    US
    BGNE
    0.00%
    HK
    06160
    -1.39%

    The Science and Technology Innovation Board's innovative drugs go overseas and "break the circle," with potential overseas BD transactions exceeding USD 12 billion in the first half of the year

    | Recently, the 2025 World Lung Cancer Conference was held in Barcelona, Spain. Innovative drug companies on the STAR Market, Beigene, Biokin Pharmaceutical, and Dizal Pharmaceutical, all had important research selected for this year's conference oral presentations. The overseas business development of innovative drug companies on the STAR Market has also reached a new peak. Preliminary statistics show that since 2025, innovative drug companies on the STAR Market have completed a total of 14 licensing transactions for pipeline assets, with a potential total transaction amount exceeding 12 billion USD

    Zhitong·
    SH
    688192
    +2.72%
    US
    BGNE
    0.00%
    SH
    688235
    +0.92%
    Zhitong·
    SH
    688192
    +2.72%
    US
    BGNE
    0.00%
    SH
    688235
    +0.92%

    Dizal Pharmaceutical: Multiple latest research results in the field of lung cancer announced at the 2025 World Conference on Lung Cancer (WCLC)

    Dizal Pharmaceutical announced 11 latest studies on its novel lung cancer targeted drug Shuwozhe® and highly selective JAK1 inhibitor Gaoruizhe® in the field of non-small cell lung cancer at the 2025 World Conference on Lung Cancer (WCLC). The international multicenter registration clinical study "Wukong 1B" of Shuwozhe® demonstrated a favorable benefit/risk ratio in the treatment of NSCLC with EGFR exon 20 insertion mutations. The research on Gaoruizhe® showed that its combination with anti-PD-1 monoclonal antibody treatment for advanced NSCLC is controllable in terms of safety

    Zhitong·
    SH
    688192
    +2.72%
    Zhitong·
    SH
    688192
    +2.72%
    © 2025 Longbridge｜Disclaimer